Preclinical development of monoclonal antibodies: Considerations for the use of non-human primates

AUTOR(ES)

Chapman, Kathryn

FONTE

Landes Bioscience

RESUMO

The development of mAbs remains high on the therapeutic agenda for the majority of pharmaceutical and biotechnology companies. Often, the only relevant species for preclinical safety assessment of mAbs are non-human primates (NHPs), and this raises important scientific, ethical and economic issues. To investigate evidence-based opportunities to minimize the use of NHPs, an expert working group with representatives from leading pharmaceutical and biotechnology companies, contract research organizations and institutes from Europe and the USA, has shared and analyzed data on mAbs for a range of therapeutic areas. This information has been applied to hypothetical examples to recommend scientifically appropriate development pathways and study designs for a variety of potential mAbs. The addendum of ICHS6 provides a timely opportunity for the scientific and regulatory community to embrace strategies which minimize primate use and increase efficiency of mAb development.

Documentos Relacionados

• A Monoclonal Antibody Selection for Immunohistochemical Examination of Lymphoid Tissues From Non-human Primates
• Non‐human primates: the appropriate subjects of biomedical research?
• HEART MEASUREMENTS OF NON-HUMAN PRIMATES BY RADIOGRAPHIC TECHNIQUES
• Detection of antibodies to Oropouche virus in non-human primates in Goiânia City, Goiás
• Borrelia burgdorferi transcriptome in the central nervous system of non-human primates